

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO. 6779	
10/665,883 09/		09/19/2003	Chong-Sheng Yuan	466992001100		
25225	7590	02/02/2006		EXAMINER		
		ERSTER LLP	PATTERSON, CHARLES L JR			
12531 HIGH SUITE 100	1 BLUFF	DRIVE	ART UNIT	PAPER NUMBER		
SAN DIEG	O, CA 9	2130-2040	1652			
				DATE MAILED: 02/02/2000	6	

Please find below and/or attached an Office communication concerning this application or proceeding.

	•	Application No).	Applicant(s)	
	10/665,883	YUAN, CHONG-SHENG		SHENG	
Office Action Su	Examiner Art Unit				
		Charles L. Patt	erson, Jr.	1652	
The MAILING DATE of t Period for Reply	his communication ap	pears on the cov	er sheet with the o	correspondence ac	dress
A SHORTENED STATUTORY WHICHEVER IS LONGER, FR - Extensions of time may be available und after SIX (6) MONTHS from the mailing - If NO period for reply is specified above, - Failure to reply within the set or extende Any reply received by the Office later the earned patent term adjustment. See 37	ROM THE MAILING D ler the provisions of 37 CFR 1.1 date of this communication. the maximum statutory period d period for reply will, by statute an three months after the mailin	ATE OF THIS C 136(a). In no event, how will apply and will expire, cause the application	COMMUNICATION Wever, may a reply be tire SIX (6) MONTHS from to become ABANDONE	N. mely filed the mailing date of this of the COUNTY (35 U.S.C. § 133).	
Status					
 1) Responsive to communication 2a) This action is FINAL. 3) Since this application is closed in accordance wi 	2b)⊠ This in condition for allowa	s action is non-fi ince except for fo	nal. ormal matters, pre	osecution as to the	e merits is
Disposition of Claims					
4)) <u>1-30</u> is/are withdraw lowed. ected. pjected to.	n from considera			
Application Papers					
9)⊠ The specification is object 10)⊠ The drawing(s) filed on 1 Applicant may not request Replacement drawing sheet 11)□ The oath or declaration is	9 September 2003 is/ that any objection to the et(s) including the correc	are: a)⊠ accept drawing(s) be hel tion is required if t	d in abeyance. Se he drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 C	FR 1.121(d).
Priority under 35 U.S.C. § 119					
2. Certified copies of3. Copies of the cert	None of: the priority document the priority document ified copies of the prione International Burea	ts have been rec ts have been rec rity documents h u (PCT Rule 17.	ceived. ceived in Applicat nave been receive 2(a)).	ion No ed in this National	Stage
Attachment(s) 1) Motice of References Cited (PTO-89 2) Motice of Draftsperson's Patent Drav		4)	Interview Summary Paper No(s)/Mail D		
3) Information Disclosure Statement(s) Paper No(s)/Mail Date		5) <u> </u>	Notice of Informal F	Patent Application (PT	O-152)

Application/Control Number: 10/665,883

Art Unit: 1652

Applicants' election with traverse of Group IV, claims 50-72 in the reply filed on 12/27/05 is acknowledged. The traversal is on the ground(s) that Groups III and IV are in the same class and subclass and there would be no undue search burden. After further consideration the examiner will examine Groups III and IV, claims 31-72. It is noted that applicant characterize Group IV as claims 50-77, but apparently it should be claims 50-72 as there are only 72 claims present in the application.

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 12/27/06.

The disclosure is objected to because of the following informalities:

On page 27, line 6, the recitation of "lithium" is apparently incorrect. This example is dealing with sodium detection and therefore the instant recitation should apparently be "sodium".

The recitation of "Toluidin" at the end of the legend to Table 6 is apparently incorrect. Apparently the correct recitation should be "Toluidine" as in Table 3 and claims 44, 47, 67 and 71.

Appropriate correction is required.

Claims 35, 43, 49, 56 and 66 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim must refer to the claims in the alternative only. See MPEP \$ 608.01(n).

Application/Control Number: 10/665,883

Art Unit: 1652

Claims 35-36, 43, 45, 47, 49-50, 56-57, 60, 66, 69 and 71 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 35, 43, 49, 56 and 66 are confusing because the claims are dependent upon a non-elected claim.

Claims 36 and 57 are confusing because the arrow does not extend the full length of the term above the arrow. Parts of the term above the arrow might be construed as belonging to the words below it.

Claim 45 is confusing and apparently incorrect in the recitation of "kit of" on line 1, which should apparently be "kit for".

Claims 47 and 71 are confusing in the recitation of "if sodium [lithium] ions are not present". Apparently the specification teaches that the amount of sodium [or lithium] ions present can be determined from the reaction scheme in Tables 3 and 6, and therefore sodium [or lithium] ions are apparently present if product is formed, just a decreasing amount of product is formed with increasing sodium [or lithium].

Claim 50 is confusing in the recitation of "(b)" in line 6. Apparently the correct recitation should be "(a)".

Claim 60 is confusing in the recitation of "a adenosine 3',5'-bisphosphate" in lines 3-4. This instant recitation infers that there is more than one adenosine 3',5'-bishosphate and furthermore the instant recitation should be "an adenosine 3',5'-bisphosphate". Apparently the "a" should be left out as was done in claim 39.

Claim 69 is incorrect in the recitation of "futher", which should apparently be "further".

Application/Control Number: 10/665,883

Art Unit: 1652

•

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 31-72 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

To begin with, the recitation of "Intra-assay", Inter-assay" and "CV%" in Table 4 and Table 7 is not understood. What do these terms refer to?

The instant claims are drawn to "contacting the sample with a sodium-sensitive [or lithium-sensitive] 3'(2'), 5'-bisphosphate nucleotidase". The specification does not teach which 3'(2'), 5'-bisphosphate nucleotidases are sodium-sensitive and which are lithium-sensitive. Without such a teaching one of ordinary skill in the art would be unable to perform the claimed methods. The specification states that "any suitable 3'(2'),5'-bisphosphate nucleotidase can be used" (paragraph 66 and 91) and gives as examples SEQ ID NO:4 and 5 in each paragraph. The specification does not state which 3'(2'),5'-bisphosphate nucleotidases are sensitive to sodium and which ones are sensitive to lithium. Presumably the enzymes of both SEQ ID NO:4 and 5 cannot be sensitive to both or else the assay could not distinguish sodium from lithium.

Apparently the specification teaches the use of a 3'(2'), 5'-bisphosphate nucleotidase that is sensitive to either sodium or lithium to distinguish sodium or lithium ions in the sample. This is done by first making a calibration curve with low and high concentrations of the two ions and then

Art Unit: 1652

5

seeing where on the calibration curve the unknown sample falls. It is not seen how the chimeric protein containing a leader sequence fits into this.

Is the purpose of this simply to provide a stable enzyme by including a leader sequence?

It is maintained that one of ordinary skill in the art could not practice the claimed invention without undue experimentation.

No art rejection is being made. The examiner could find nothing in the prior art that would anticipate of make obvious the claimed invention.

Lopez-Coronado, et al. (U) and Lurganov, et al. (V) are cited as of interest.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charles L. Patterson, Jr., PhD, whose telephone number is 571-272-0936. The examiner can normally be reached on Monday - Friday from 7:30 to 4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the

Application/Control Number: 10/665,883 Page 6

Art Unit: 1652

Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-

9197 (toll-free).

Charles L. Patterson, Jr.

Primary Examiner Art Unit 1652

Patterson January 27, 2006